高流量鼻导管氧疗治疗新型冠状病毒肺炎的价值。
The value of high-flow nasal cannula oxygen therapy in treating novel coronavirus pneumonia.
机构信息
Department of Respiratory and Critical Care Medicine, No. 2 People's Hospital of Fuyang City, Fuyang, China.
Department of Respiratory and Critical Care Medicine, No. 2 People's Hospital of Wuhu City, Wuhu Anhui, China.
出版信息
Eur J Clin Invest. 2021 Mar;51(3):e13435. doi: 10.1111/eci.13435. Epub 2020 Oct 31.
OBJECTIVE
This study aimed to investigate the value of high-flow nasal cannula (HNFC) oxygen therapy in treating patients with severe novel coronavirus pneumonia (COVID-19).
METHODS
The clinical data of 22 patients with severe COVID-19 were collected. The heart rate (HR), respiratory rate (RR) and oxygenation index (PO /FiO ) at 0, 6, 24 and 72 hours after treatment were compared between the HFNC oxygen therapy group and the conventional oxygen therapy (COT) group. In addition, the white blood cell (WBC) count, lymphocyte (L) count, C-reactive protein (CRP) and procalcitonin (PCT) were compared before and at 72 hours after oxygen therapy treatment.
RESULTS
The differences at 0 hours between the two groups were not statistically significant. Compared with COT group,in the HFNC oxygen therapy group, HR, RR and PaO /FiO were better at 6 hours after treatment, PaO /FiO was better at 24 and 72 hours. After 72 hours, L and CRP had improved in the HFNC oxygen therapy group compared with the COT group, but the differences in WBC and PCT were not statistically significant. The length of stay in the intensive care unit (ICU) and the total length of hospitalization was shorter in the HFNC oxygen therapy group than in the COT group.
CONCLUSION
Compared with COT, early application of HFNC oxygen therapy in patients with severe COVID-19 can improve oxygenation and RR, and HFNC oxygen therapy can improve the infection indexes of patients and reduce the length of stay in the ICU of patients. Therefore, it has high clinical application value.
目的
本研究旨在探讨高流量鼻导管（HFNC）氧疗在治疗新型冠状病毒肺炎（COVID-19）重型患者中的价值。
方法
收集 22 例重型 COVID-19 患者的临床资料，比较 HFNC 氧疗组与常规氧疗（COT）组患者治疗后 0、6、24、72 小时的心率（HR）、呼吸频率（RR）和氧合指数（PO/FiO ）。此外，比较两组患者氧疗治疗前和治疗后 72 小时的白细胞（WBC）计数、淋巴细胞（L）计数、C 反应蛋白（CRP）和降钙素原（PCT）。
结果
两组患者在 0 小时时的差异无统计学意义。与 COT 组相比，HFNC 氧疗组患者在治疗后 6 小时时 HR、RR 和 PaO/FiO 更好，在 24 和 72 小时时 PaO/FiO 更好。HFNC 氧疗组患者在治疗后 72 小时时 L 和 CRP 较 COT 组改善，但 WBC 和 PCT 差异无统计学意义。HFNC 氧疗组患者在重症监护病房（ICU）的住院时间和总住院时间均短于 COT 组。
结论
与 COT 相比，HFNC 氧疗早期应用于重型 COVID-19 患者可以改善氧合和 RR，HFNC 氧疗可以改善患者的感染指标，减少患者 ICU 的住院时间，因此具有较高的临床应用价值。
Zotero 插件